Mirum Pharmaceuticals Inc. Common Stock (MIRM)

FairStock Score: 39/100 — MIXED

Key Financials

Strengths

• Generates $167 million in annual free cash flow (3.0% yield on market cap)
• Altman Z-Score of 5.8 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 49.8% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration

AI Analysis

Mirum Pharmaceuticals Inc. Common Stock is a small-cap healthcare company valued at $5.5 billion. Revenue stands at $570 million, though the company is currently unprofitable. From a quality standpoint, Mirum shows Altman Z-Score of 5.8 confirms fortress-level solvency and negative ROE indicating losses. On valuation, the stock is 0.1% FCF yield. Growth dynamics show revenue growing at 49.8% and profit growth of 75.9%. Our composite FairStock Score of 39/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Mirum's 50% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $167 million in annual free cash flow (3.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer